Rituximab, a monoclonal antibody against CD20, is a component of standard therapy for systemic DLBCL (R-CHOP). Since most patients with PCNSL have CD20, rituximab may also play a role in the treatment of PCNSL. At the same time, intraventricular administration of rituximab has also been shown to be feasible and possibly active.